Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VivoSim Labs, Inc. - Common Stock (NQ:VIVS)

0.9901 -0.0699 (-6.59%)
Streaming Delayed Price Updated: 12:28 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about VivoSim Labs, Inc. - Common Stock

News headline image
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Announces Pricing of up to a $4 Million Public Offering
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with... 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevance 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platforms 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
Roadzen Inc. (NASDAQ: RDZN) Accelerates U.S. Expansion with Strategic Acquisition – Surges on Record Volume – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market 
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
From VivoSim Labs, Inc.
Via GlobeNewswire
News headline image
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
From VivoSim Labs, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.